<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Starting from identical patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, we compared the 20-year predictions of two computer simulation models, a 1998 version of the IMIB model and version 2.17 of the Global <z:mp ids='MP_0002055'>Diabetes</z:mp> Model (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Primary measures of outcome were 20-year cumulative rates of: survival, first (incident) <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>), first <z:hpo ids='HP_0001297'>stroke</z:hpo>, proliferative diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PDR</z:e>), macro-<z:mp ids='MP_0002871'>albuminuria</z:mp> (gross <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, or GPR), and <z:mpath ids='MPATH_686'>amputation</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Standardized test patients were newly diagnosed males aged 45 or 75, with high and low levels of glycated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (HbA(1c)), systolic blood pressure (SBP), and serum <z:chebi fb="23" ids="18059">lipids</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Both models generated realistic results and appropriate responses to changes in risk factors </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e>, the IMIB model predicted much higher rates of mortality and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>, and fewer <z:hpo ids='HP_0001297'>strokes</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>These differences can be explained by differences in model architecture (Markov vs. microsimulation), different evidence bases for cardiovascular prediction (Framingham Heart Study cohort vs. Kaiser Permanente patients), and isolated versus interdependent prediction of cardiovascular events </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with IMIB, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> predicted much higher lifetime costs, because of lower mortality and the use of a different costing method </plain></SENT>
<SENT sid="7" pm="."><plain>It is feasible to cross-validate and explicate dissimilar <z:mp ids='MP_0002055'>diabetes</z:mp> simulation models using standardized patients </plain></SENT>
<SENT sid="8" pm="."><plain>The wide differences in the model results that we observed demonstrate the need for cross-validation </plain></SENT>
<SENT sid="9" pm="."><plain>We propose to hold a second 'Mt Hood Challenge' in 2001 and invite <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> modelers to attend </plain></SENT>
</text></document>